Loading...
In women younger than 50, vulvar and vaginal cancers are often related to infection with human papillomavirus (HPV). The new quadrivalent HPV vaccine, promoted to prevent cervical cancer, is also FDA-approved for prevention of precancerous lesions of the cervix, vulva, and vagina. Here, the manufacturer presents data on prevention of precancerous high-grade vulvar and vaginal intraepithelial lesions.
In three related multinational trials, investigators randomized 18,150 women aged 16 to 26 to receive three doses of either quadrivalent HPV vaccine or placebo over 6 months; follow-up averaged 3 years. Among women who completed the full protocol, none in the vaccine group and 15 in the placebo group developed high-grade vulvovaginal lesions rel…